Vol 10, No 5 (2021)
Research paper
Published online: 2021-06-15

open access

Page views 6336
Article views/downloads 380
Get Citation

Connect on Social Media

Connect on Social Media

Serum Adenosine Deaminase and C - reactive protein in Diabetic patients with and without Neuropathy

Mansoor Khan1, Anju Muraleedharan2, Saleena Ummer Velladath3, Manjunath Hande4
Clin Diabetol 2021;10(5):407-411.


Background: Diabetic Peripheral Neuropathy (DPN) is one major microvascular complication of long-standing diabetes mellitus with a prevalence of 50-60%. DPN leads to decreased quality of life, increased morbidity, and mortality. C reactive protein (CRP) and Adenosine deaminase (ADA) are independent inflammatory markers; the current study aims to evaluate and compare serum ADA, CRP in diabetic patients with and without neuropathy. Materials and Methods: A prospective study was done on 160 diabetic patients with and without neuropathy who visited the Medicine department of Kasturba hospital Manipal. Patients grouped into two, diabetic with neuropathy (n=80) and without Neuropathy (n=80). Serum samples were collected and analysed for CRP and ADA. Results: The data were analyzed using the Independent t-test and Mann-Whitney U test. There was a significantly high level of ADA (p=0.032) in neuropathy patients when compared with the non-DPN group. No significant difference was seen in CRP levels (p=0.123) in DPN patients compared to non-DPN patients. Conclusion: Monitoring of inflammatory markers like ADA in diabetic patients can provide insight into preventing DPN and its associated complications.

Article available in PDF format

View PDF Download PDF file


  1. Yuen L, Saeedi P, Riaz M, et al. Projections of the prevalence of hyperglycaemia in pregnancy in 2019 and beyond: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157: 107841.
  2. Patterson CC, Karuranga S, Salpea P, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157: 107842.
  3. Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J. Harrison’s principles of internal medicine. Mcgraw Hill Education, New York Chicago San Francisco 2018.
  4. Vinik AI, Nevoret M-L, Casellini C, Parson H. Diabetic Neuropathy. Endocrinology and Metabolism Clinics of North America 2020;42(4):747–787. https://www.sciencedirect.com/science/article/abs/pii/S0889852913000522?via%3Dihub (17.05.2020).
  5. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and Oxidative Stress in Diabetic Neuropathy: Futuristic Strategies Based on These Targets. International Journal of Endocrinology. 2014. https://www.hindawi.com/journals/ije/2014/674987/ (17.05.2020).
  6. M. Wilson N, E. Wright D. Inflammatory Mediators in Diabetic Neuropathy. Journal of Diabetes & Metabolism 2012 ;01(S5). https://www.longdom.org/open-access/inflammatory-mediators-in-diabetic-neuropathy-2155-6156.S5-004.pdf (17.05.2020).
  7. Song SO, Kim KJ, Lee B-W, Kang ES, Cha BS, Lee HC. Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis. 2012;225(2):450–455. https://www.atherosclerosis-journal.com/article/S0021-9150(12)00618-1/fulltext (17.05.2020).
  8. Xu F, Zhao LH, Su JB, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014; 6(1): 139.
  9. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993; 91(4): 1351–7.
  10. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. Journal of Clinical Investigation. 2003;111(12):1805–12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161431/ (17.05.2020).
  11. Franco R, Valenzuela A, Lluis C, et al. Enzymatic and extra enzymatic role of ecto-adenosine deaminase in lymphocytes. Immunological Reviews. 1998 Feb. ; 161(1): 27–42.
  12. Hoshino T, Yamada K, Masuoka K, Tsuboi I, Itoh K, Nonaka K, Oizumi K. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Research and Clinical Practice. 1994;25(2):97–102. https://www.diabetesresearchclinicalpractice.com/article/0168-8227(94)90034-5/pdf (17.05.2020).
  13. Aruna S, Suchitra M, Suresh V. Adenosine deaminase activity in type 2 diabetes mellitus. J Clin Scientific Res. 2017; 6(4): 254.
  14. Prakash M, Chennaiah S, Murthy Y, Anjaiah E, Rao A, Suresh C. Altered Adenosine Deaminase Activity in Type 2 Diabetes Mellitus. JIACM. 2006;7(2):114–21. http://medind.nic.in/jac/t06/i2/jact06i2p114.pdf (17.05.2020).
  15. Pop-Busui R, Ang L, Holmes C, et al. Inflammation as a Therapeutic Target for Diabetic Neuropathies. Curr Diab Rep. 2016; 16(3): 29.